With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five ...

The US Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for ...

Cartesian Therapeutics Inc. unveiled 12-month efficacy and safety data from the phase IIb trial of Descartes-08 in participants with generalized myasthenia gravis (MG). Participants dosed with a ...

FacebookTweetPin It was only yesterday that BlackRock CEO Larry Fink said that “we’re probably in a recession” right now.

Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the ...

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Potential Alumis Inc. (NASDAQ:ALMS) shareholders may wish to note that the Independent Director, Alan Colowick, recently bought US$130k worth of stock, paying US$7.04 for each share. Although the ...

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheetBoards unanimously recommend stockholders ...

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be comple ...